MediciNova confirms Phase 3 trial of ibudilast in progressive MS
Category: #health  By Mateen Dalal  Date: 2019-07-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

MediciNova confirms Phase 3 trial of ibudilast in progressive MS

Ibudilast could be the best-in-disease drug for MS patients with unmet medical needs

MediciNova, Inc., a biopharmaceutical company that develops novel therapeutics and is traded on Tokyo Stock Exchange’s JASDAQ Market and on NASDAQ Global Market, recently announced the plans for a Phase 3 clinical study of MN-166 (ibudilast) in progressive multiple sclerosis patients after a feedback from the U.S. Food and Drug Administration (FDA).

Apparently, Phase 3 clinical trial of MediciNova will be enrolling subjects who are suffering from secondary progressive multiple sclerosis without relapses. It is MediciNova’s believe that subjects who have secondary progressive MS without any relapses will give the best response clinically to MN-166 treatment compared to any other type of progressive MS.

According to previous reports by MediciNova, MN-116’s SPRINT-MS Phase 2b trial in progressive MS depicted that the reduced risks of confirmed disability progression trend, as EDSS measured, is the highest for the subjects put in a subgroup suffering from secondary progressive MS sans relapses. MN-166 (ibudilast) showed a risk reduction of 46% as compared to placebo, indicated by 0.538 of hazard ratio.

Reportedly, for long-term secondary progressive treatment MS sans relapses, that is the largest subgroup of patients with progressive MS, there is no approved drugs as compared to primary and secondary progressive relapses. Following the conclusion of recently finished progressive MS’ clinical trial, MediciNova has found that over 80% of patients who have secondary progressive MS do not suffer from relapses.

MediciNova’s President and Chief Executive Officer, Yuichi Iwaki, MD, PhD., said that despite the approval of FDA given for two drugs, there has been significant unmet medical need for patients with secondary progressive MS without any relapses. The company believes ibudilast can become the best-in-disease drug with favorable safety, tolerability and convenient oral administration.

The National MS society reports that MS affects nearly 2.3 million people globally, where around 85% of patients are diagnosed with relapsing remitting MS initially.

 

Source credit- https://investors.medicinova.com/news-releases/news-release-details/medicinova-announces-phase-3-clinical-trial-plan-mn-166

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Industrial Sludge Treatment Chemicals Market is projected to showcase significant growth from paper & pulp sectors
Industrial Sludge Treatment Chemicals Market is projected to showcase significant growth from paper & pulp sectors
By Mateen Dalal

The Industrial Sludge Treatment Chemicals Market is set to grow from its current market value of more than $4.5 billion to over $7.5 billion by 2024; as reported in the latest study by Global Market Insights, Inc. Industrial Sludge Treatment Chemica...

Linear Alpha Olefins Market will show exponential growth in the coming years
Linear Alpha Olefins Market will show exponential growth in the coming years
By Mateen Dalal

The Linear Alpha Olefins Market is set to grow from its current market value of more than $12 billion to over $19 billion by 2024; as reported in the latest study by Global Market Insights, Inc. In the recent times, Linear Alpha Olefins market has c...

Canopy Rivers’ joint venture awarded Health Canada cultivation license
Canopy Rivers’ joint venture awarded Health Canada cultivation license
By Mateen Dalal

PharmHouse’s greenhouse facility in Ontario is reportedly one of the largest in the world Canopy Rivers Inc, Canopy Growth Corp’s venture capital arm, has recently announced that its PharmHouse Joint venture has secured a license for cul...